|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Since the neuropeptide Y (NPY) system has been reported to be involved in the pathophysiology of anxiety and in particular panic disorder and the genes coding for NPY Y1, Y2, and Y5 receptors are located in the suggested risk region (4q31-q32), variants in the NPY, NPY Y1, Y2, and Y5 genes were investigated for association with panic disorder in a sample of 230 German patients with panic disorder and matched healthy controls.
|
17948870 |
2008 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide Y (NPY) was shown to modulate anxiety- and depression-related behaviors in various animal models.
|
16691011 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
For example, NPY is consistently involved in anxiety-related behaviors and there is increasing support for a role of this peptide in mood disorders such as depression.
|
16611091 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Neuropeptide Y (NPY) is a major endogenous regulator of anxiety-related behaviors and emotionality.
|
15897713 |
2005 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Extensive animal studies suggest neuropeptide Y (NPY) to be involved in coping with a wide range of stressors, and that impaired central NPY signalling could be involved in the pathophysiology of anxiety and depression.
|
14757324 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We found correspondence between linkage and microarray/candidate gene studies for genes involved with the mitogen-activated protein kinase (MAPK) signaling system, nuclear factor kappa B (NFKB) complex, neuropeptide Y (NPY) neurotransmission, a nicotinic receptor subunit (CHRNA2), the vesicular monoamine transporter (SLC18A2), genes in pathways implicated in human anxiety (HTR7, TDO2, and the endozepine-related protein precursor, DKFZP434A2417), and the micro 1-opioid receptor (OPRM1).
|
15048644 |
2004 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
It is suggested that NPY may influence ethanol consumption by regulating basal levels of anxiety, by modulating the sedative effects of ethanol, and/or by modulating ethanol's rewarding properties.
|
15337375 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Following recovery, a test of anxiety was conducted in which the rats (n = 12-13/group) received either artificial cerebrospinal fluid (aCSF) or NPY (10 microg) 10 min prior to a 5-min test on an elevated plus maze.
|
12824809 |
2003 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
I also suggest that, via CREB, NPY might interact with other CREB target genes, such as the gene encoding brain-derived neurotrophic factor, and that this CREB-mediated interaction might be important in the regulation of anxiety and alcohol drinking behaviors.
|
12967770 |
2003 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings point to the potential of the NPY system for developing novel pharmacological treatments of stress-related disorders, including anxiety and depression.
|
12013027 |
2002 |
|
Anxiety Disorders
|
0.400 |
Therapeutic
|
group |
CTD_human |
The Y1 receptor antagonist blocked the anxiolytic-like effect of neuropeptide Y, while the Y2 receptor antagonist was ineffective.We conclude that neuropeptide Y in the dorsocaudal lateral septum may act as an endogenous anxiolytic and antagonize corticotropin-releasing hormone (stress)-induced anxiety.
|
11440811 |
2001 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Because of the widespread distribution of NPY, it has been implicated in the modulation of a variety of behaviors, including, but not limited to, circadian rhythms /1/, memory retention /33/, feeding /19,56/, sympathetic control of cardiovascular function /89/ and anxiety /42,43/.
|
9711903 |
1998 |